Staffan Encrantz Biography and Net Worth

Director of Sight Sciences

Founder and Chairman of Allegro Investment Fund, L.P., a registered Cayman Islands Investment Fund that is managed by Allegro Investment Inc. Located in Menlo Park, CA, Allegro primarily invests in growth stage private companies and supports its portfolio by providing growth capital as well as strategic, operating and financial expertise.
Mr. Encrantz has actively led investments in and operation of a variety of companies for over 30 years. He has led the growth and development of both early stage companies and established businesses in a wide variety of fields.
Mr. Encrantz is currently Chairman of AnaMar AB, ClosingCorp Inc, Evolve Controls, LLC, Nclear Inc, Alestra Ltd., Koncentra Holding AB and the Koncentra Verkstads AB group. He is also a director of GovX, Inc, Oxymetal SAS and several other companies.

Mr. Encrantz previously worked at ASEA AB, Sweden (now ABB Ltd.), as its deputy General Counsel 1979-1981, as Finance Manager 1981-1984, and during 1984-1990 in Switzerland and the UK as Business Area manager responsible for ABB’s Commodity Trading and Counter Trading group. Prior to this, he worked at Skandia Insurance Co, Sweden as its General Counsel and in private law practice.

Mr. Encrantz holds a law degree (Magna cum Laude) from Uppsala University, Sweden.

What is Staffan Encrantz's net worth?

The estimated net worth of Staffan Encrantz is at least $2.09 million as of May 16th, 2022. Mr. Encrantz owns 301,802 shares of Sight Sciences stock worth more than $2,094,506 as of October 6th. This net worth evaluation does not reflect any other investments that Mr. Encrantz may own. Learn More about Staffan Encrantz's net worth.

How do I contact Staffan Encrantz?

The corporate mailing address for Mr. Encrantz and other Sight Sciences executives is 4040 CAMPBELL AVE SUITE 100, MENLO PARK CA, 94025. Sight Sciences can also be reached via phone at 877-266-1144 and via email at [email protected] Learn More on Staffan Encrantz's contact information.

Has Staffan Encrantz been buying or selling shares of Sight Sciences?

Staffan Encrantz has not been actively trading shares of Sight Sciences over the course of the past ninety days. Most recently, on Monday, May 16th, Staffan Encrantz bought 300,000 shares of Sight Sciences stock. The stock was acquired at an average cost of $8.20 per share, with a total value of $2,460,000.00. Following the completion of the transaction, the director now directly owns 301,802 shares of the company's stock, valued at $2,474,776.40. Learn More on Staffan Encrantz's trading history.

Who are Sight Sciences' active insiders?

Sight Sciences' insider roster includes Staffan Encrantz (Director), and Jesse Selnick (CFO). Learn More on Sight Sciences' active insiders.

Are insiders buying or selling shares of Sight Sciences?

In the last year, Sight Sciences insiders bought shares 6 times. They purchased a total of 1,139,910 shares worth more than $21,744,764.26. The most recent insider tranaction occured on May, 16th when Director Staffan Encrantz bought 300,000 shares worth more than $2,460,000.00. Insiders at Sight Sciences own 44.3 % of the company. Learn More about insider trades at Sight Sciences.

Information on this page was last updated on 5/16/2022.

Staffan Encrantz Insider Trading History at Sight Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2022Buy300,000$8.20$2,460,000.00301,802View SEC Filing Icon  
5/13/2022Buy1,802$7.98$14,379.961,802View SEC Filing Icon  
12/1/2021Buy214,606$22.40$4,807,174.40View SEC Filing Icon  
11/29/2021Buy86,454$18.85$1,629,657.90View SEC Filing Icon  
10/18/2021Buy527,048$24.00$12,649,152.00View SEC Filing Icon  
See Full Table

Staffan Encrantz Buying and Selling Activity at Sight Sciences

This chart shows Staffan Encrantz's buying and selling at Sight Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sight Sciences Company Overview

Sight Sciences logo
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $6.94
Low: $6.86
High: $7.10

50 Day Range

MA: $7.81
Low: $6.10
High: $10.16

2 Week Range

Now: $6.94
Low: $5.95
High: $27.70


4,639 shs

Average Volume

297,171 shs

Market Capitalization

$331.94 million

P/E Ratio


Dividend Yield